388P Subgroup analysis of patients (pts) with HER2-low metastatic breast cancer (mBC) with brain metastases (BMs) at baseline from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC)
Tsurutani, J., Jacot, W., Yamashita, T., Riaz, F., Yerushalmi, R., Im, S-A., Niikura, N., Halser-Strub, U., Cortés, J., Wennstig, A-K., Chae, Y., Wang, X., Li, W., Simon, H., Masci, G., Tamburini, E., Aguilar, C. Orbegoso, Tecson, K., Yung, L., Modi, S.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article